Orexigen™ Preclinical Results Show Contrave™Acts on Specific Pathways in the Brain to Reduce Food Intake

Orexigen™ Therapeutics, Inc. announced on October 23, 2007, that preclinical tests showed that a combination of bupropion and naltrexone (the two drugs making up the Orexigen™ drug Contrave™) resulted in a 94% reduction of food intake in obese mice, greater than either drug alone, and as much as 77% reduction in lean mice.

For more information on this press release, go to http://ir.orexigen.com/releasedetail.cfm?ReleaseID=270737.

Technorati Tags: Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion